Why did Novo Nordisk stock drop 27% this week?

Two drivers hit at once. Management guided 2026 revenue to a 5–13% decline, which cut growth expectations. At the same time, risk from semaglutide copycats rose as telehealth players explored a Wegovy pill angle. That mix pressured pricing assumptions and confidence, sending the stock sharply lower before a Friday rebound.

What is in the 2026 revenue guidance and why does it matter?

The company flagged a 5–13% revenue decline for 2026. That suggests slower growth and potential pricing pressure. It matters because prior expectations were higher. Lower sales can push margins down, reduce cash returns, and compress valuation. Investors now want clear proof on demand, costs, and brand protection.

How could the Hims & Hers lawsuit affect Novo?

If Novo pursues a Hims & Hers lawsuit and wins, it could deter semaglutide copycats, support pricing, and protect brand equity. Adverse outcomes, or slow action, may keep pressure on sentiment. FDA support for enforcement helped Friday’s bounce, but investors still need concrete legal milestones to regain confidence.

Is Novo Nordisk stock attractive for Swiss investors now?

It depends on risk tolerance. Valuation near 13x PE and a roughly 2.6% yield help, but 2026 guidance and copycat risks keep volatility high. Consider position sizing, FX exposure, and legal catalysts. A data-driven plan with clear stops and review dates can make the risk more manageable.

What should investors watch next?

Focus on legal steps and any FDA actions on unapproved products, pricing updates in key markets, and supply metrics. Track sentiment through technicals and volume. The next checkpoint is the 6 May 2026 earnings report, where management can update the 2026 revenue guidance and margin outlook for Novo Nordisk stock.

Global Market Insights

NVO Stock Today, February 9: 27% Weekly Slide; FDA Backs Copycat Fight

ByHuzaifa Zahoor February 10, 2026

Novo Nordisk stock slid 27% this week after management signalled a 5–13% decline in 2026 revenue, far below market hopes. Sentiment worsened as telehealth players pushed into a potential Wegovy pill and semaglutide copycats. On Friday, shares rebounded after the company vowed legal action, with FDA support, against unauthorized products. For Swiss investors, the mix of guidance risk, pricing pressure, and litigation headlines calls for discipline, attention to FX, and a clear plan for position sizing in healthcare portfolios.